Thalidomide is an inhibitor of angiogenesis.
Open accessAbstract
Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay. Experiments including the analysis of thalidomide analogs revealed that the antiangiogenic activity correlated with the teratogenicity but not with the sedative or the mild immunosuppressive properties of thalidomide. Electron microscopic examination of the corneal neovascularization of thalidomide-treated rabbits revealed specific ultrastructural changes similar to those seen in the deformed limb bud vasculature of thalidomide-treated embryos. These experiments shed light on the mechanism of thalidomide's teratogenicity and hold promise for the potential use of thalidomide as an orally administered drug for the treatment of many diverse diseases dependent on angiogenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MG degraders are already a therapeutic reality.
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [56]
In the 1990s, thalidomide was reconsidered as an anticancer agent.
“In the 1990s, thalidomide was reconsidered as an anticancer agent7.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [7]
Cites
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191 · see citing works
Fràter‐Schröder, M., Risau, W., Hallmann, R., Gautschi-Sova, P., & Böhlen, P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5277 · Cited by 698 · see citing works
Thalidomide in the treatment of lepra reactions
Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 534 · see citing works
A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment
Crum, R. M., Szabó, S., & Folkman, J. (1985) · Science · doi:10.1126/science.2416056 · Cited by 489 · see citing works
Self-citationA simple procedure for the long-term cultivation of chicken embryos
Auerbach, R., Kubai, L., Knighton, D. R., et al. (1974) · Developmental Biology · doi:10.1016/0012-1606(74)90316-9 · Cited by 443 · see citing works
Discovery of a New Mechanism and Development of Angiogenic Therapy That Accelerates Healing
Folkman, J., Szabó, S., Stovroff, M. C., McNeil, P. L., Li, W. W., & Shing, Y. (1991) · Annals of Surgery · doi:10.1097/00000658-199110000-00006 · Cited by 277 · see citing works
Self-citationThalidomide teratogenesis: evidence for a toxic arene oxide metabolite.
Gordon, G., Spielberg, S. P., Blake, D. A., et al. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2545 · Cited by 153 · see citing works
The sequence of events in the regression of corneal capillaries.
Ausprunk, D. H., Falterman, K., & Folkman, J. (1978) · PubMed · Cited by 140 · see citing works
Self-citationProposed mechanisms of action in thalidomide embryopathy
Stephens, T. D. (1988) · Teratology · doi:10.1002/tera.1420380307 · Cited by 114 · see citing works
Lim, S. K. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90312-1 · Cited by 56 · see citing works
Effect of Thalidomide on the Graft versus Host Reaction
Field, E. O., Gibbs, J. E., Tucker, D. F., et al. (1966) · Nature · doi:10.1038/2111308a0 · Cited by 47 · see citing works
Fc, H., FRANKUS, E., Friderichs, E., Graudums, I., & Flohé, L. (1981) · PubMed · Cited by 46 · see citing works
Keenan, R. J., Eiras, G., Burckart, G. J., et al. (1991) · PubMed · Cited by 45 · see citing works
Early changes in limb buds of chick embryos after thalidomide treatment
JURAND, A. (1966) · Development · doi:10.1242/dev.16.2.289 · Cited by 42 · see citing works
Sunderkötter, C. H., Roth, J., & Sorg, C. (1990) · PubMed · Cited by 37 · see citing works
THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION
Saurat, J. ‐., Camenzind, M., Helg, C., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91151-8 · Cited by 33 · see citing works
Cytokinetic studies on the aortic endothelium and limb bud vascularization in avian embryos
Seifert, R., Zhao, B., & Christ, B. (1992) · Anatomy and Embryology · doi:10.1007/bf00186983 · Cited by 28 · see citing works
Teratologic studies on the Himalayan rabbit: new aspects of thalidomide-induced teratogenesis
Sterz, H., Nothdurft, H. D., Lexa, P., & Ockenfels, H. (1987) · Archives of Toxicology · doi:10.1007/bf00295758 · Cited by 28 · see citing works
McCarthy, D., Kanfer, E., & Barrett, A. J. (1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90089-9 · Cited by 27 · see citing works
A comparative study of total body irradiation as a method of inducing granulocyte depletion in mice
Bogman, M. J. J. T., Cornelissen, I. M. H. A., Berden, J. H. M., Jong, J. D., & Koene, R. A. P. (1984) · Journal of Immunological Methods · doi:10.1016/0022-1759(84)90386-7 · Cited by 9 · see citing works
Thalidomide-Like Malformations Caused by a Tween Surfactant in Mice
Kocher-Becker, U., Kocher, W., & Ockenfels, H. (1981) · Zeitschrift für Naturforschung C · doi:10.1515/znc-1981-9-1038 · Cited by 9 · see citing works
[Studies in experiment animals and dysmelia syndrome].
Helm, F. (1966) · PubMed · Cited by 8 · see citing works
ALLOGENEIC BONE MARROW TRANSPLANTATION IN IRRADIATED ADULT RABBITS
Bigelow, C. L., Adler, L., & Appelbaum, F. R. (1987) · Transplantation · doi:10.1097/00007890-198709000-00005 · Cited by 5 · see citing works
[RESEARCH ON THE TERATOGENIC EFFECT OF 2-DIETHYLAMINOPROPIOPHENONE].
CAHEN, R. L., Sautai, M., & MONTAGNE, J. (1964) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627 · see citing works
Self-citationDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · see citing works
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · see citing works
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332 · see citing works
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209 · see citing works
Self-citationStructure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959 · see citing works
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912 · see citing works
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880 · see citing works
Adipose tissue mass can be regulated through the vasculature
Rupnick, M. A., Panigrahy, D., Zhang, C.-Y., Dallabrida, S. M., Lowell, B. B., Langer, R., & Folkman, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162349799 · Cited by 845 · see citing works
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814 · see citing works
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748 · see citing works
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669 · see citing works
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509 · see citing works
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512 · see citing works
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382 · see citing works
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317 · see citing works
Zhu, Y. X., Kortuem, K. M., & Stewart, A. K. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.728597 · Cited by 293 · see citing works
Novel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246 · see citing works
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246 · see citing works
Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood · doi:10.1182/blood-2014-02-557819 · Cited by 213 · see citing works
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197 · see citing works
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200 · see citing works
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022123-104147 · Cited by 178 · see citing works
Lenalidomide enhances anti-myeloma cellular immunity
Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J. I., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1308-3 · Cited by 162 · see citing works
Clinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150 · see citing works
Obesity and the Risk for Cardiovascular Disease
Rashid, M. N., Fuentes, F., Touchon, R. C., & Wehner, P. S. (2003) · Preventive Cardiology · doi:10.1111/j.1520-037x.2003.01358.x · Cited by 146 · see citing works
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
The clinical significance of cereblon expression in multiple myeloma
Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.08.015 · Cited by 113 · see citing works
Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0632 · Cited by 110 · see citing works
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95 · see citing works
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84 · see citing works
Circulating Endothelial Progenitor Cells Are Up-Regulated in a Mouse Model of Endometriosis
Becker, C. M., Beaudry, P., Funakoshi, T., Benny, O., Zaslavsky, A., Zurakowski, D., Folkman, J., D'Amato, R. J., & Ryeom, S. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.12.037 · Cited by 81 · see citing works
Self-citationThe application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76 · see citing works
Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis
Nakamura, M., Katsuki, Y., Shibutani, Y., & Oikawa, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00765-7 · Cited by 63 · see citing works
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69 · see citing works
Phase I study of oral lenalidomide in patients with refractory metastatic cancer
Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335001 · Cited by 56 · see citing works
Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Wilczynski, J., Duechler, M., & Czyz, M. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0132-3 · Cited by 41 · see citing works
Clinical trials with anti‐angiogenic agents in hematological malignancies
Medinger, M., & Mross, K. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-10 · Cited by 40 · see citing works
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40 · see citing works
The history of angiogenesis inhibitors
Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15 · see citing works
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 10 · see citing works
- Authors
- D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J.
- Affiliations
- Department of Surgery, Children's Hospital, Harvard Medical School, Boston 02115.
- Harvard University (US)
- ORCID
- Flynn, E
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1994-04-26
- Volume
- 91
- Issue
- 9
- Pages
- 4082-4085
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC43727
- OpenAlex
- W1985147506
- Cited by
- 2,454
- References
- 24
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 40 · 2023: 46 · 2022: 40 · 2021: 54 · 2020: 60 · 2019: 49 · 2018: 51 · 2017: 48 · 2016: 66 · 2015: 72 · 2014: 59 · 2013: 87 · 2012: 100
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and biological activity
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- thalidomide, angiogenesis inhibition, teratogenicity, basic fibroblast growth factor, corneal neovascularization, thalidomide analogues, dysmelia, anti-angiogenic therapy
- MeSH terms
- Animals, Chick Embryo, Cornea, Neovascularization, Pathologic, Rabbits, Thalidomide, Fibroblast Growth Factor 2, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
